want to survive in the investment field, keen sense of smell, quick action, and accurate judgment are indispensable. Good investment projects can be cut off the day before signing.
Not to mention a project with high certainty and bright prospects like Kechuang Biology. After reading the first phase clinical report of endorphin, investors have only one thought in mind: I want to grab this project.
Cheng Gang said helplessly: "You should know that you have done research on Kechuang Biology. Zheng Dong is a person who is dedicated to research. After the first phase of the clinical trial report came out, Mr. Lei came to Gusu for inspection and proposed to have dinner with Zheng Dong."
"They eat They were all eaten in our company cafeteria, and the chat ended within 20 minutes after eating, and Mr. Zheng continued to work in the laboratory."
"Mr. Zheng spends more than 14 hours in the laboratory every day. I don't have time to go out to eat."
"The boss is more diligent than the employees below, I feel ashamed. The first thing Mr. Lei said to me after dinner with Mr. Zheng was: If such a person is not successful, who can succeed? "
The second sentence is: the scariest thing is that people who are more talented than you work harder than you."
Stephanie said with emotion: "You have to trust Goldman Sachs' research capabilities, which are written in our research report. We want to Investing in Kechuangbio is not only for endorphins."
"More importantly, I want to vote for Zheng Li, a top scientific research genius combined with unparalleled hard work, and he is still so young. Zheng Li can at least support The development of Kechuang Biology in the next 30 years."
"I am very willing to come to your company to have a meal and chat with Mr. Zheng."
Cheng Gang replied: "Sorry, the first person who called before was IDG Young, Zheng Dong really don't want to meet anyone."
Young Guo from IDG is an undergraduate student in the Department of Applied Chemistry of Shenhai Jiaotong University and a doctorate degree in polymer chemical engineering from Massachusetts State University. He is the first to realize Outside investors to Zheng Li's value.
At the beginning of the establishment of Kechuang Bio, Young expressed his hope to participate in the first round of venture capital, but at that time, Zheng Li and Lei Jun had no intention to increase capital and share.
"However, we will hold a sharing session later, when we have new research results to be announced, and at the same time we will talk about the details of the second round of investment."
"The sharing session should be in these two days."
June Gusu Fenghe On a sunny afternoon, many investors gathered in the open conference room of Kechuang Biotech, and Kechuangbio only sent invitation letters to the top domestic investment institutions.
Before the sharing session started, the investors had already exchanged words.
"Hong Bo, when will CMB International invest in biopharmaceutical companies?"
"Sci-tech biotech and CMB International's investment philosophy may not match, right?" Young from IDG Capital and Wang Hongbo from CMB International said while chatting.
Among the venture capital institutions active in China, apart from foreign capital such as IDG Capital, Sequoia, Goldman Sachs, and Morgan, there are also venture capital departments established by domestic first-tier banks in China, Agriculture, Industry, Construction, Communications, and Recruitment.
These banks generally set up their own venture capital departments around 2011.
Wang Hongbo chuckled and said: "That's not what you said. China Merchants Bank once led the investment in Kangtai Biotech and helped Kangtai Biotech to be listed on the GEM. We have always been committed to investing in outstanding domestic innovative companies and growing together with excellent companies."
Young I thought to myself, who doesn't know who, what are you pretending here: "I'm afraid the only biopharmaceutical company CMB International has invested in over the years is Kangtai Biotech.
" I am afraid that you and I know the specific purpose of China Merchants Bank International's investment in Kangtai Biotech when it is listed on the ChiNext Board."
"Science and Technology Biotech will not be listed so soon, can China Merchants Bank International be able to stand the loneliness?"
Wang Hongbo said with a smile: "This You don't need to worry about it, we plan to get involved in venture capital in the biopharmaceutical industry from this year onwards, and we are very optimistic about companies related to the localization of biomedicine."
Cold knowledge: CMB International invested in Kangtai Biology in 2015, and has never invested in the biomedical industry since then. However, in 2020 and 2021, it invested in five companies in the biomedical industry in one go.
The reason is very simple. After the 18-year trade war, the country proposed a requirement for domestically produced equipment to replace foreign equipment in the background of financial institutions, which is the so-called "de-IOEization". .
According to the same logic, the biopharmaceutical industry also wants to realize the top-level will to replace imports with domestic production, so pharmaceutical stocks and pharmaceutical-related venture capital have begun to rise.
Young: "CMB Capital can only help Sci-Tech Biotech in terms of capital operation, but IDG Capital can help Sci-Tech Biotech in an all-round way. Our investment experience in the biomedical industry is not comparable to that of CMB International."
In 2020 Years ago, IDG Capital's investment experience in the biomedical industry was indeed much richer than that of CMB International. They began to invest in companies in the biomedical industry since 1996.
Among them, the 2007 A-round venture capital investment of Jiuan Medical, the most popular demon stock, was led by IDG Capital.
In addition, don't think that the investment industry is so high and powerful. When a really good project appears, they will use any dirty means as long as they are useful. Wang Hongbo: "If you only look at the investment experience in the industry, then I don't think there is any need for Kechuang Bio to send invitation letters to the
bank's venture capital.
"
Take it easy, your competitor is not me, your competitor is Goldman Sachs and Morgan, and my competitor is Bank of Communications International, CCB International, China Venture Capital, and CICC."
"Quality companies like Kechuang Biotech Enterprises will definitely not introduce all foreign capital."
Young Guo replied: "I am just curious, and CMB International would not invest in enterprises of this nature."
"You are right, but According to my information, the final decision is in the hands of Zheng Dong, and he has not met any representative of any investment institution."
"Now everyone is on the same starting line."
"Seeing Director Zheng's resume, I am feeling that there are really geniuses in this world. In the second round of venture capital investment, we have at least doubled the valuation of Kechuang Biotech." , 5 billion RMB."
"Zheng Dongcai was 18 years old and worth more than 4 billion RMB, and I was still doing test tubes in Shenhai when I was 18 years old."
Wang Hongbo: "People are different. My understanding is that he is a top scientific research talent."
"But I think he is not only gifted in scientific research ability, but also in decisiveness and judgment. After publishing nature, he directly chooses to leave school and start a business. After meeting with Lei Jun, I received 50 million venture capital." "
After getting the venture capital, every step of the way is just right."
"I have to feel that the world will eventually belong to young people."